Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Kobulnicky (NPI 1245676477)

Field	Value
Entity Type	Individual
Organization	David Kobulnicky
Address	3000 Coliseum Dr Ste 104
City	Hampton
State	VA
ZIP	23666
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 15, 2013

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider is operating as a hematology/oncology infusion practice: the Medicare code mix is dominated by high-cost oncology biologics (J9271, J9144, J9299) alongside chemotherapy and infusion administration codes such as 96413, 96401, 96365, and 96375, and routine oncology lab panels. That combination indicates an office or clinic structure set up to deliver in‑person infusions and on-site monitoring rather than a purely consultative or diagnostic practice.

Revenue is highly concentrated in a few biologic drug codes: J9271 ($1.2M, 41.5%), J9144 ($648K, 22.6%), and J9299 ($332.2K, 11.6%) account for 75.7% of this provider's total Medicare revenue. This top-three concentration (75.7%) shows the practice’s financial reliance on administration of a small set of high-cost agents.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $3M and there is no Medicaid billing on file. The absence of Medicaid activity suggests the provider’s Medicare caseload is the dominant or sole public-payer revenue stream captured in these records.

National competitive standing on the largest drug codes is mixed: J9271 ranks #166 of 1841 (91th percentile; typical, unremarkable volume for this code), and J9144 ranks #64 of 615 (90th percentile; typical, unremarkable volume for this code), indicating solid but not outsized national presence for those agents. By contrast, J9299 ranks #243 of 505 (52th percentile; typical, unremarkable volume for this code), showing a more modest national position for nivolumab compared with the practice’s stronger daratumumab and pembrolizumab volumes.

Evaluation-and-management billing is unusually high relative to peers: 99213 is an extreme outlier at the 98th percentile (far above typical national volume) and 99214 sits at the 93th percentile (notably above typical national volume). These elevated E/M volumes suggest heavy office-based follow-up and patient management activity, which is consistent with frequent infusion visits and ongoing oncology care.

On-site laboratory and monitoring services appear significant: 80053 and 85025 both rank in the 98th percentile (typical, unremarkable volume for 80053; typical, unremarkable volume for 85025) and 85055 ranks in the 96th percentile (notably above typical national volume). High volumes of CMP, CBC, and platelet/reticulocyte testing align with active chemotherapy and biologic therapy management requiring frequent lab surveillance.

The provider has an established Medicare tenure, with NPI enumeration on 2013-05-15 (~13 years ago), which combined with $3M in lifetime Medicare revenue indicates a sustained oncology practice presence in the market. This longevity supports the interpretation that current code mix and volumes reflect an ongoing business model rather than a short-term spike.

Operational and reimbursement risk is concentrated: because 75.7% of Medicare revenue is tied to three J‑codes (J9271, J9144, J9299) and associated infusion services, shifts in utilization, biosimilar adoption, or reimbursement changes for these agents could materially affect the practice’s revenue. The practice’s reliance on in‑office administration and frequent E/M and lab testing also means operational capacity (infusion chairs, nursing) likely drives revenue generation and would be a key leverage point for payers and partners to consider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,600	$40	$1.2M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	18,000	$40	$648K
J9299	Injection, nivolumab, 1 mg	15,100	$20	$332.2K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,510	$30	$153.3K
J0897	Injection, denosumab, 1 mg	6,000	$20	$108K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	640	$90	$59.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	890	$60	$56.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	510	$100	$51K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	18,210	$1	$36.4K
88185	The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with…	1,430	$20	$25.7K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

David Kobulnicky — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	110	12,800	$40	$610.9K
J9299	10	30	12,920	$20	$335.4K
J9144	3	60	8,280	$40	$332.7K
J0897	79	340	2,820	$20	$89.3K
J1568	3	30	1,990	$30	$81.8K
J0881	18	80	10,200	$1	$34.5K
88185	8	60	620	$20	$34.3K
Q5122	25	40	270	$90	$32.5K
96413	29	230	250	$100	$28.5K
J9217	80	130	140	$130	$23.9K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Kobulnicky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Virginia Oncology Associates	VA	Hematology & Oncology Physician	$0	$6.2M
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Victor Archie	VA	Radiation Oncology Physician	$4M	$0
Julia Schaefer-cutillo	NC	Hematology & Oncology Physician	$4M	$0
Mark Fleming	VA	Hematology & Oncology Physician	$3.9M	$0
Thomas Alberico	VA	Hematology & Oncology Physician	$3.5M	$0
Celesteann Bremer	VA	Hematology & Oncology Physician	$2.8M	$0
Bo Zhao	VA	Hematology & Oncology Physician	$2.6M	$0
Michael Lee	VA	Specialist	$2.3M	$0
Ligeng Tian	VA	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as David Kobulnicky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hampton Newport News Community Services Board	VA	Community/Behavioral Health Agency	$0	$123.8M
Sentara Hospitals	VA	General Acute Care Hospital	$0	$78.5M
Serenity C & C Inc.	VA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$74.2M
Agape Counseling & Therapeutic Services, Inc	VA	Community/Behavioral Health Agency	$0	$18.5M
Alliance Behavioral Counseling	VA	Community/Behavioral Health Agency	$0	$16.9M
Hampton Mental Health Associates, Inc	VA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$12M
United And Empowered Care, Inc	VA	Developmentally Disabled Services Day Training Agency	$0	$11.8M
Better Life Services, Inc.	VA	Community/Behavioral Health Agency	$0	$9.2M
Creating Scholars Through Therapy, LLC	VA	Community/Behavioral Health Agency	$0	$7.6M
Key Elements Care, LLC	VA	In Home Supportive Care Agency	$0	$6.8M

David Kobulnicky — Billing Profile & Reimbursement Data

Sign up for David Kobulnicky — Billing Profile & Reimbursement Data policy alerts

David Kobulnicky — Billing Profile & Reimbursement Data

Sign up for David Kobulnicky — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References